

## Oncology

**Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities in oncology and cancer immunology.**

### **Our Oncology Partnering Focus**

We are seeking in-licensing and collaborative opportunities at discovery, pre-clinical and clinical stages, for therapeutic programs in our interest areas.

#### **Cancer cell-directed therapies:**

- Growth signaling e.g. RTKs, Wnt, Notch, KRAS, MET, MYC, MEK
- Regulation of apoptosis
- Epigenetic regulation
- Regulation of protein homeostasis.

#### **Immune cell-directed therapies:**

- Myeloid cell-targeting therapies and innate immune stimulatory pathways
- Tumor stromal concepts and targets
- Cancer vaccines and oncolytic viruses
- Novel tumor antigens for coupling to our T cell engager (TcE) platforms

**If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...**

**Working together  
for better health**

**For more information please contact our BD&L team:**

**Dr. Scott M. DeWire**  
[scott.dewire@boehringer-ingelheim.com](mailto:scott.dewire@boehringer-ingelheim.com)

**Dr. Emilio Erazo-Fischer**  
[emilio.erazo-fischer@boehringer-ingelheim.com](mailto:emilio.erazo-fischer@boehringer-ingelheim.com)

**Dr. Marcio Lasaro**  
[marcio.lasaro@boehringer-ingelheim.com](mailto:marcio.lasaro@boehringer-ingelheim.com)

